| Literature DB >> 30001402 |
Jaroslaw Thomas Dankert1, Marc Wiesehöfer1, Elena Dilara Czyrnik1, Bernhard B Singer1, Nicola von Ostau1, Gunther Wennemuth1.
Abstract
Prostate carcinoma contain foci of neuroendocrine transdifferentiation, resulting in an increase of androgen-independent neuroendocrine-like (NE) tumor cells, whose number significantly correlates with tumor aggressiveness and thus lower survival rate. Neuroendocrine transdifferentiation of prostate cancer cells and a potential role of miRNAs within this process are poorly understood. MicroRNAs are small non-coding RNAs which post-transcriptionally regulate gene expression. The aim of this project was to identify new genes and miRNAs involved in neuroendocrine transdifferentiation. LNCaP prostate cancer cells were differentiated to NE-like cancer cells and microarray analyses were performed. Microarray results have been validated for the eight most deregulated mRNAs and microRNAs via qRT-PCR and analyzed with different algorithms to predict new targets for deregulated microRNAs. The induced CyclinD1 gene could be validated as new target gene for the repressed miR-17 family containing miR-17, miR-20a, miR-20b, miR-106a and miR-106b via reporter gene assays and Western Blot. Functional analysis of miR-17 family shows a high influence on cell proliferation, colony forming ability and apoptosis in LNCaP cells. Our data demonstrate wide changes in mRNA and microRNA expression during neuroendocrine transdifferentiation of LNCaP cells and confirm new mRNA-miRNA interactions with potential roles in NE-transdifferentiation of prostate carcinoma.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30001402 PMCID: PMC6042731 DOI: 10.1371/journal.pone.0200472
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Neuroendocrine transdifferentiation of LNCaP cells through androgen deprivation.
(A) LNCaP cells were cultivated in media with charcoal-stripped FCS (CS-FCS) or control FCS for 14 days. Transdifferentiated cells show dendrite like cell processes indicated by black arrows. (B) Successful transdifferentiation was validated through time course expression analysis of AR, PSA, NSE, NTS and TUBB3 in transdifferentiated LNCaP cells compared to untreated cells during androgen deprivation for 14 days by RT-PCR. Beta-actin and GAPDH served as endogenous controls.
Differentially expressed genes in neuroendocrine differentiated LNCaP cells compared to untreated LNCaP cells.
| Gene title | Gene symbol | Ratio (log2) |
|---|---|---|
| kallikrein-related peptidase 3 | KLK3 | -10.8 |
| kallikrein-related peptidase 2 | KLK2 | -10.5 |
| ADAM metallopeptidase domain 7 | ADAM7 | -7.6 |
| NK3 homeobox 1 | NKX3-1 | -7.5 |
| potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 | KCNN2 | -7.2 |
| transmembrane protein with EGF-like and two follistatin-like domains 2 | TMEFF2 | -6.9 |
| mucin 5B, oligomeric mucus/gel-forming | MUC5B | -6.8 |
| family with sequence similarity 20, member A | FAM20A | -6.5 |
| male germ cell-associated kinase | MAK | -6.4 |
| connector enhancer of kinase suppressor of Ras 2 | CNKSR2 | -6.3 |
| microseminoprotein, beta- | MSMB (PSP94) | -6.2 |
| regulatory factor X, 6 | RFX6 | -6.2 |
| KIAA1210 | KIAA1210 | -6.1 |
| thymosin beta 15a / thymosin beta 15B | TMSB15A/TMSB15B | -6.0 |
| glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | GRIN3A | -5.6 |
| fibroblast growth factor 9 (glia-activating factor) | FGF9 | -5.5 |
| neuropilin (NRP) and tolloid (TLL)-like 1 | NETO1 | -5.5 |
| keratin associated protein 9–9 | KRTAP9-9 | -5.4 |
| transmembrane protease, serine 2 | TMPRSS2 | -5.4 |
| AF4/FMR2 family, member 3 | AFF3 | -5.4 |
| keratin 34 | KRT34 | 8.8 |
| secretogranin V (7B2 protein) | SCG5 | 7.2 |
| G protein-coupled receptor 115 | GPR115 | 6.4 |
| keratin 33A | KRT33A | 5.9 |
| keratin associated protein 1–5 | KRTAP1-5 | 5.3 |
| keratin 7 | KRT7 | 5.2 |
| cytoplasmic polyadenylation element binding protein 1 | CPEB1 | 5.0 |
| interleukin 13 receptor, alpha 2 | IL13RA2 | 4.8 |
| neutrophil cytosolic factor 2 | NCF2 | 4.8 |
| transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase) | TGM2 | 4.7 |
| aldo-keto reductase family 1, member B10 (aldose reductase) | AKR1B10 | 4.6 |
| insulin-like growth factor binding protein 3 | IGFBP3 | 4.6 |
| Rho GTPase activating protein 27 | ARHGAP27 | 4.6 |
| sidekick cell adhesion molecule 2 | SDK2 | 4.6 |
| RUN and FYVE domain containing 2 | RUFY2 | 4.6 |
| nervous system abundant protein 11 | NSAP11 | 4.5 |
| CD33 molecule | CD33 | 4.4 |
| transforming growth factor, beta 2 | TGFB2 | 4.4 |
| adhesion molecule with Ig-like domain 2 | AMIGO2 | 4.4 |
| keratin 80 | KRT80 | 4.4 |
Differentially expressed miRNAs in neuroendocrine differentiated LNCaP cells compared to untreated LNCaP cells.
| miRNA | Ratio (log2) | miRNA | Ratio (log2) |
|---|---|---|---|
| hsa-miR-720 | 4.62 | hsa-miR-126 | -4.57 |
| hsa-miR-3135b | 3.84 | hsa-miR-148a | -4.33 |
| hsa-miR-3178 | 3.81 | hsa-miR-141 | -4.03 |
| hsa-miR-424* | 3.56 | hsa-miR-203 | -3.97 |
| hsa-miR-23a* | 3.48 | hsa-miR-18b | -3.96 |
| hsa-miR-29b-1* | 3.09 | hsa-miR-18a | -3.88 |
| hsa-miR-27a* | 2.88 | hsa-miR-3613-5p | -3.41 |
| hsa-miR-1280 | 2.78 | hsa-miR-497 | -3.40 |
| hsa-miR-1296 | 2.62 | hsa-miR-4521 | -3.19 |
| hsa-miR-378g | 2.58 | hsa-miR-301a | -2.99 |
| hsa-miR-139-5p | 2.45 | hsa-miR-34a | -2.83 |
| hsa-miR-4656 | 2.43 | hsa-miR-1246 | -2.75 |
| hsa-miR-3615 | 2.39 | hsa-miR-17* | -2.60 |
| hsa-miR-1260 | 2.28 | hsa-miR-4668-5p | -2.47 |
| hsa-miR-663 | 2.26 | hsa-miR-29c | -2.40 |
| hsa-miR-664* | 2.20 | hsa-miR-374b | -2.38 |
| hsa-miR-504 | 2.19 | hsa-miR-148b | -2.37 |
| hsa-miR-4665-5p | 2.13 | hsa-miR-3613-3p | -2.32 |
| hsa-miR-378d | 2.12 | hsa-miR-20b | -2.25 |
| hsa-miR-3195 | 2.12 | hsa-miR-105 | -2.25 |
| hsa-miR-3609 | 2.09 | hsa-miR-1287 | -2.19 |
| hsa-miR-4467 | 2.01 | hsa-miR-25* | -2.04 |
| hsa-miR-4667-5p | 1.96 | hsa-miR-20a | -1.96 |
| hsa-miR-378f | 1.95 | hsa-miR-26b | -1.95 |
| hsa-miR-4454 | 1.94 | hsa-miR-93* | -1.92 |
| hsa-miR-193a-5p | 1.83 | hsa-miR-3935 | -1.88 |
| hsa-miR-181b | 1.82 | hsa-miR-195 | -1.86 |
| hsa-miR-4443 | 1.80 | hsa-miR-3065-5p | -1.84 |
| hsa-miR-3197 | 1.76 | hsa-miR-200a* | -1.83 |
| hsa-miR-30b* | 1.76 | hsa-miR-15a | -1.82 |
| hsa-miR-122 | 1.74 | hsa-miR-330-3p | -1.80 |
| hsa-miR-422a | 1.71 | hsa-miR-106a | -1.79 |
| hsa-miR-221* | 1.64 | hsa-miR-106b | -1.78 |
| hsa-miR-1260b | 1.62 | hsa-miR-17 | -1.77 |
| hsa-mir-3676 | 1.61 | hsa-miR-1202 | -1.65 |
| hsa-miR-494 | 1.59 | hsa-mir-548a | -1.60 |
| hsa-miR-197 | 1.55 | hsa-miR-660 | -1.58 |
| hsa-miR-4508 | 1.55 | hsa-miR-200c | -1.55 |
| hsa-miR-181a-2* | 1.52 | hsa-miR-339-5p | -1.53 |
| hsa-miR-378i | 1.50 | hsa-miR-1180 | -1.53 |
| hsa-miR-181a | 1.49 | hsa-miR-500a | -1.49 |
| hsa-miR-320e | 1.44 | hsa-miR-128 | -1.47 |
| hsa-miR-4492 | 1.43 | hsa-miR-21* | -1.45 |
| hsa-miR-378 | 1.40 | hsa-miR-4324 | -1.45 |
| hsa-miR-378* | 1.40 | hsa-miR-1269 | -1.44 |
| hsa-miR-505* | 1.39 | hsa-mir-200c | -1.41 |
| hsa-miR-378e | 1.36 | hsa-miR-19a | -1.38 |
| hsa-miR-181c | 1.36 | hsa-mir-425 | -1.36 |
| hsa-miR-196a | 1.36 | hsa-miR-2392 | -1.35 |
| hsa-miR-1908 | 1.34 | hsa-miR-93 | -1.30 |
Fig 2Validation of differentially expressed genes in NE-differentiated LNCaP cells compared to untreated cells.
The expression of eight mRNAs (A, B) and miRNAs (C, D) that were assumed to be elevated or reduced according to their signals in microarray (black bars) was assessed by qRT-PCR (grey bars). Results represent the mean from 4 independent NE-transdifferentiations performed in duplicates (*, p<0.05).
Classification of deregulated genes in LNCaP after NETD according to GO terms with p-value <0.05.
(A) GO enrichment results for repressed genes (Top 20). (B) GO enrichment results for induced genes (Top 20).
| GO description | Count | p-value | |
|---|---|---|---|
| oxidation-reduction process | 35 | 1,20E-03 | |
| cell division | 31 | 1,70E-06 | |
| mitotic nuclear division | 27 | 1,90E-07 | |
| cell proliferation | 25 | 1,10E-03 | |
| proteolysis | 25 | 4,10E-02 | |
| cell adhesion | 23 | 4,90E-02 | |
| cellular protein metabolic process | 19 | 5,50E-08 | |
| CENP-A containing nucleosome assembly | 18 | 8,90E-15 | |
| sister chromatid cohesion | 18 | 3,90E-08 | |
| positive regulation of gene expression | 18 | 6,00E-03 | |
| double-strand break repair via nonhomologous end joining | 17 | 1,30E-10 | |
| negative regulation of gene expression, epigenetic | 16 | 3,60E-11 | |
| nucleosome assembly | 16 | 8,10E-06 | |
| positive regulation of gene expression, epigenetic | 15 | 9,70E-09 | |
| telomere capping | 14 | 3,80E-14 | |
| telomere organization | 14 | 5,90E-13 | |
| DNA-templated transcription, initiation | 14 | 5,10E-11 | |
| gene silencing by RNA | 14 | 7,00E-05 | |
| chromosome segregation | 13 | 1,90E-06 | |
| regulation of cell cycle | 12 | 2,60E-03 | |
| positive regulation of transcription from RNA polymerase II promoter | 60 | 5,20E-05 | |
| signal transduction | 56 | 1,80E-02 | |
| negative regulation of transcription from RNA polymerase II promoter | 38 | 1,60E-02 | |
| positive regulation of cell proliferation | 35 | 6,20E-05 | |
| positive regulation of transcription, DNA-templated | 35 | 4,10E-04 | |
| oxidation-reduction process | 35 | 4,20E-03 | |
| negative regulation of apoptotic process | 33 | 2,00E-04 | |
| cell adhesion | 32 | 5,00E-04 | |
| negative regulation of transcription, DNA-templated | 28 | 2,00E-02 | |
| negative regulation of cell proliferation | 27 | 2,00E-03 | |
| inflammatory response | 23 | 1,70E-02 | |
| angiogenesis | 21 | 1,40E-04 | |
| cell-cell signaling | 21 | 7,70E-04 | |
| positive regulation of gene expression | 20 | 2,70E-03 | |
| cellular protein metabolic process | 17 | 4,30E-06 | |
| extracellular matrix organization | 17 | 1,70E-03 | |
| positive regulation of angiogenesis | 16 | 1,40E-05 | |
| nucleosome assembly | 16 | 2,10E-05 | |
| positive regulation of cell migration | 16 | 2,40E-03 | |
| small GTPase mediated signal transduction | 16 | 3,00E-02 |
Pathway analysis of deregulated genes in LNCaP after NETD according with p-value <0.05.
(A) Pathway enrichment results for repressed genes. (B) Pathway enrichment results for induced genes.
| Pathway | Count | p-value | |
|---|---|---|---|
| Metabolic pathways | 55 | 4,80E-02 | |
| Viral carcinogenesis | 24 | 7,90E-07 | |
| PI3K-Akt signaling pathway | 20 | 3,70E-02 | |
| Systemic lupus erythematosus | 17 | 1,80E-05 | |
| Alcoholism | 17 | 5,10E-04 | |
| Biosynthesis of antibiotics | 14 | 3,80E-02 | |
| Transcriptional misregulation in cancer | 12 | 3,60E-02 | |
| p53 signaling pathway | 10 | 5,40E-04 | |
| Progesterone-mediated oocyte maturation | 10 | 3,50E-03 | |
| Cell cycle | 10 | 3,20E-02 | |
| FoxO signaling pathway | 10 | 4,80E-02 | |
| Protein digestion and absorption | 9 | 1,20E-02 | |
| Arginine and proline metabolism | 8 | 1,80E-03 | |
| ECM-receptor interaction | 8 | 3,40E-02 | |
| Prostate cancer | 8 | 3,60E-02 | |
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 7 | 3,90E-02 | |
| Pentose and glucuronate interconversions | 6 | 8,30E-03 | |
| Glycine, serine and threonine metabolism | 5 | 4,80E-02 | |
| Pathways in cancer | 25 | 2,10E-02 | |
| Viral carcinogenesis | 18 | 3,00E-03 | |
| Alcoholism | 17 | 1,60E-03 | |
| Systemic lupus erythematosus | 14 | 2,30E-03 | |
| Hematopoietic cell lineage | 10 | 6,10E-03 | |
| TNF signaling pathway | 10 | 2,40E-02 | |
| TGF-beta signaling pathway | 9 | 1,70E-02 | |
| Malaria | 8 | 2,90E-03 | |
| Cytosolic DNA-sensing pathway | 8 | 1,30E-02 | |
| Legionellosis | 7 | 1,90E-02 | |
| NOD-like receptor signaling pathway | 7 | 2,10E-02 |
Fig 3Deregulated genes in the KEGG pathway “cell cycle” in LNCaP cells after NETD.
The pathway enrichment result for “cell cycle” (hsa04110) shows repressed genes marked with red asterisks and induced genes marked with blue asterisks.
Fig 4Quantification of CCND1 and miRNA expression in neuroendocrine transdifferentiated LNCaP cells compared to untreated LNCaP cells and predicted miRNA target sites.
The expression of CCND1 and miR-17 family miRNAs (A) that were assumed to be elevated or reduced according to their signals in microarray (black bars) was assessed by qRT-PCR (grey bars). CCND1 was predicted to be elevated while miR-17, miR-20a, miR-20b, miR-106a, miR-106b and miR-93 were predicted to be reduced in NE-transdifferentiated LNCaP as compared to untreated cells (*, p<0.05). (B) A schematic representation of the predicted miRNA interaction site and the mutated seed sequences are shown. (C) The 3’UTR region of CCND1 is depicted.
Fig 5Response of CCND1 3’UTR and protein expression towards miR-17 family.
(A) The CCND1 3’UTR was cloned behind the luciferase reporter gene of the pMIR vector and the potential binding site for the indicated miRNAs in the 3’UTR was additionally mutated by site directed mutagenesis (CCND1 mut). The reporter gene construct was expressed with the miRNA expression construct or with the empty pSG5 vector as control in the indicated combinations. Results represent the mean of at least four independent experiments performed in duplicates. The dashed line represents the luciferase activity of the empty luciferase reporter plasmid with the empty pSG5 vector which was set to 100% (***, p<0.001). (B) LNCaP cells were transfected either with control vector or miRNA expression vectors. 48 hours post-transfection the protein expression of CCND1 was determined by Western blot using ß-actin as loading control. The densitometrical quantification of Western Blots represents the relative downregulation of CCND1 expression as determined in three independent experiments in relation to the corresponding ß-actin band as loading control.
Fig 6Effect of miR-17 family on cell growth, colony formation and apoptosis of LNCaP cells.
LNCaP cells were transfected either with control vector or miRNA expression vectors and seeded in a limited cell number. Cell growth was determined by automated cell counting of parallel experiments at 24, 48 and 72 h post transfection for three independent experiments (A). Eight days after seeding, colonies were stained with crystal violet (B). Colony formation was quantified by densitometry analyses. Data show the mean and ± SEM of the densitometry analysis of three independent CFA experiments (***, p<0.001). For apoptosis analysis, LNCaP cells were harvested 72h post transfection and stained with Annexin-FITC/PI. In FACS analysis apoptosis was determined as sum of early and late apoptosis (upper/lower right quadrants). Dot blots display representative results (FL1-H: Annexin-FITC, FL3-H: PI), the right panel shows the mean of four independent experiments (C).